Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

653 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Timeliness of Initial Therapy in Multiple Myeloma: Trends and Factors Affecting Patient Care.
Kumar V, Alhaj-Moustafa M, Bojanini L, Sher T, Roy V, Manochakian R, Vishnu P, Bodepudi S, Shareef Z, Ahmed S, Jani P, Paulus A, Grover A, Alegria VR, Ailawadhi M, Chanan-Khan A, Ailawadhi S. Kumar V, et al. Among authors: roy v. JCO Oncol Pract. 2020 Apr;16(4):e341-e349. doi: 10.1200/JOP.19.00309. Epub 2020 Jan 21. JCO Oncol Pract. 2020. PMID: 32048939
Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma.
Short KD, Rajkumar SV, Larson D, Buadi F, Hayman S, Dispenzieri A, Gertz M, Kumar S, Mikhael J, Roy V, Kyle RA, Lacy MQ. Short KD, et al. Among authors: roy v. Leukemia. 2011 Jun;25(6):906-8. doi: 10.1038/leu.2011.29. Epub 2011 Feb 25. Leukemia. 2011. PMID: 21350560 Free PMC article. Clinical Trial.
Immunomodulatory drugs in multiple myeloma.
Andhavarapu S, Roy V. Andhavarapu S, et al. Among authors: roy v. Expert Rev Hematol. 2013 Feb;6(1):69-82. doi: 10.1586/ehm.12.62. Expert Rev Hematol. 2013. PMID: 23373782 Review.
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013.
Mikhael JR, Dingli D, Roy V, Reeder CB, Buadi FK, Hayman SR, Dispenzieri A, Fonseca R, Sher T, Kyle RA, Lin Y, Russell SJ, Kumar S, Bergsagel PL, Zeldenrust SR, Leung N, Drake MT, Kapoor P, Ansell SM, Witzig TE, Lust JA, Dalton RJ, Gertz MA, Stewart AK, Rajkumar SV, Chanan-Khan A, Lacy MQ; Mayo Clinic. Mikhael JR, et al. Among authors: roy v. Mayo Clin Proc. 2013 Apr;88(4):360-76. doi: 10.1016/j.mayocp.2013.01.019. Mayo Clin Proc. 2013. PMID: 23541011
Smoldering multiple myeloma requiring treatment: time for a new definition?
Dispenzieri A, Stewart AK, Chanan-Khan A, Rajkumar SV, Kyle RA, Fonseca R, Kapoor P, Bergsagel PL, McCurdy A, Gertz MA, Lacy MQ, Lust JA, Russell SJ, Zeldenrust SR, Reeder C, Roy V, Buadi F, Dingli D, Hayman SR, Leung N, Lin Y, Mikhael J, Kumar SK. Dispenzieri A, et al. Among authors: roy v. Blood. 2013 Dec 19;122(26):4172-81. doi: 10.1182/blood-2013-08-520890. Epub 2013 Oct 21. Blood. 2013. PMID: 24144641 Free PMC article. Review.
AT-101 downregulates BCL2 and MCL1 and potentiates the cytotoxic effects of lenalidomide and dexamethasone in preclinical models of multiple myeloma and Waldenström macroglobulinaemia.
Paulus A, Chitta K, Akhtar S, Personett D, Miller KC, Thompson KJ, Carr J, Kumar S, Roy V, Ansell SM, Mikhael JR, Dispenzieri A, Reeder CB, Rivera CE, Foran J, Chanan-Khan A. Paulus A, et al. Among authors: roy v. Br J Haematol. 2014 Feb;164(3):352-365. doi: 10.1111/bjh.12633. Epub 2013 Nov 17. Br J Haematol. 2014. PMID: 24236538 Free PMC article.
653 results